Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

M.C. Garassino; B.-C. Cho; J.-H. Kim; J. Mazières; J. Vansteenkiste; H. Lena; J. Corral Jaime; J.E. Gray; J. Powderly; C. Chouaid; P. Bidoli; P. Wheatley-Price; K. Park; R.A. Soo; Y. Huang; C. Wadsworth; P.A. Dennis; N.A. Rizvi; L. Paz-Ares Rodriguez; S. Novello; S. Hiret; P. Schmid; E. Laack; R. Califano; M. Maemondo; S.-W. Kim; J. Chaft; D. Vicente Baz; T. Berghmans; D.-W. Kim; V. Surmont; M. Reck; J.-Y. Han; E. Holgado Martin; C. Belda Iniesta; Y. Oe; A. Chella; A. Chopra; G. Robinet; H. Soto Parra; M. Thomas; P. Cheema; N. Katakami; W.-C. Su; Y.-C. Kim; J. Wolf; J.-S. Lee; H. Saka; M. Milella; I. Ramos Garcia; A. Sibille; T. Yokoi; E.J. Kang; S. Atagi; E. Spaeth-Schwalbe; M. Nishio; F. Imamura; N. Gabrail; R. Veillon; S. Derijcke; T. Maeda; D. Zylla; K. Kubiak; A. Santoro; M.N. Uy; S. Lucien Geater; A. Italiano; D. Kowalski; F. Barlesi; Y.-M. Chen; D. Spigel; B. Chewaskulyong; R. Garcia Gomez; R. Alvarez Alvarez; C.-H. Yang; T.-C. Hsia; F. Denis; H. Sakai; M. Vincent; K. Goto; J. Bosch-Barrera; G. Weiss; J.-L. Canon; C. Scholz; M. Aglietta; H. Kemmotsu; K. Azuma; P. Bradbury; R. Feld; A. Chachoua; J. Jassem; R. Juergens; R. Palmero Sanchez; A. Malcolm; N. Vrindavanam; K. Kubota; C. Waller; D. Waterhouse; B. Coudert; Z. Mark; M. Satouchi; G.-C. Chang; C. Herzmann; A. Chaudhry; S. Giridharan; P. Hesketh; N. Ikeda; R. Boccia; N. Iannotti; M. Haigentz; J. Reynolds; J. Querol; K. Nakagawa; S. Sugawara; E.H. Tan; T. Hirashima; S. Gettinger; T. Kato; K. Takeda; O. Juan Vidal; A. Mohn-Staudner; A. Panwalkar; D. Daniel; K. Kobayashi; G.E.I. Ladrera; C. Schulte; M. Sebastian; M. Cernovska; H. Coupkova; L. Havel; N. Pauk; J. Singh; S. Murakami; T. Csoszi; G. Losonczy; A. Price; I. Anderson; M. Iqbal; V. Torri; E. Juhasz; S. Khanani; L. Koubkova; B. Levy; R. Page; C. Bocskei; L. Crinò; D. Einspahr; C. Hagenstad; N. Juat; L. Overton; M. Garrison; Z. Szalai; ATLANTIC Investigators

doi:10.1016/S1470-2045(18)30144-X

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

M.C. Garassino, B.-C. Cho, J.-H. Kim, J. Mazières, J. Vansteenkiste, H. Lena, J. Corral Jaime, J.E. Gray, J. Powderly, C. Chouaid, P. Bidoli, P. Wheatley-Price, K. Park, R.A. Soo, Y. Huang, C. Wadsworth, P.A. Dennis, N.A. Rizvi, L. Paz-Ares Rodriguez, S. NovelloS. Hiret, P. Schmid, E. Laack, R. Califano, M. Maemondo, S.-W. Kim, J. Chaft, D. Vicente Baz, T. Berghmans, D.-W. Kim, V. Surmont, M. Reck, J.-Y. Han, E. Holgado Martin, C. Belda Iniesta, Y. Oe, A. Chella, A. Chopra, G. Robinet, H. Soto Parra, M. Thomas, P. Cheema, N. Katakami, W.-C. Su, Y.-C. Kim, J. Wolf, J.-S. Lee, H. Saka, M. Milella, I. Ramos Garcia, A. Sibille, T. Yokoi, E.J. Kang, S. Atagi, E. Spaeth-Schwalbe, M. Nishio, F. Imamura, N. Gabrail, R. Veillon, S. Derijcke, T. Maeda, D. Zylla, K. Kubiak, A. Santoro, M.N. Uy, S. Lucien Geater, A. Italiano, D. Kowalski, F. Barlesi, Y.-M. Chen, D. Spigel, B. Chewaskulyong, R. Garcia Gomez, R. Alvarez Alvarez, C.-H. Yang, T.-C. Hsia, F. Denis, H. Sakai, M. Vincent, K. Goto, J. Bosch-Barrera, G. Weiss, J.-L. Canon, C. Scholz, M. Aglietta, H. Kemmotsu, K. Azuma, P. Bradbury, R. Feld, A. Chachoua, J. Jassem, R. Juergens, R. Palmero Sanchez, A. Malcolm, N. Vrindavanam, K. Kubota, C. Waller, D. Waterhouse, B. Coudert, Z. Mark, M. Satouchi, G.-C. Chang, C. Herzmann, A. Chaudhry, S. Giridharan, P. Hesketh, N. Ikeda, R. Boccia, N. Iannotti, M. Haigentz, J. Reynolds, J. Querol, K. Nakagawa, S. Sugawara, E.H. Tan, T. Hirashima, S. Gettinger, T. Kato, K. Takeda, O. Juan Vidal, A. Mohn-Staudner, A. Panwalkar, D. Daniel, K. Kobayashi, G.E.I. Ladrera, C. Schulte, M. Sebastian, M. Cernovska, H. Coupkova, L. Havel, N. Pauk, J. Singh, S. Murakami, T. Csoszi, G. Losonczy, A. Price, I. Anderson, M. Iqbal, V. Torri, E. Juhasz, S. Khanani, L. Koubkova, B. Levy, R. Page, C. Bocskei, L. Crinò, D. Einspahr, C. Hagenstad, N. Juat, L. Overton, M. Garrison, Z. Szalai, ATLANTIC Investigators

Research output: Contribution to journal › Article › peer-review

Original language	Undefined/Unknown
Pages (from-to)	521-536
Number of pages	16
Journal	The Lancet Oncology
Volume	19
Issue number	4
DOIs	https://doi.org/10.1016/S1470-2045(18)30144-X
Publication status	Published - 2018

Access to Document

10.1016/S1470-2045(18)30144-X

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85043475986&doi=10.1016%2fS1470-2045%2818%2930144-X&partnerID=40&md5=e5a4d9a64dc723014fb28cae887ec8ea

Cite this

Garassino, M. C., Cho, B-C., Kim, J-H., Mazières, J., Vansteenkiste, J., Lena, H., Corral Jaime, J., Gray, J. E., Powderly, J., Chouaid, C., Bidoli, P., Wheatley-Price, P., Park, K., Soo, R. A., Huang, Y., Wadsworth, C., Dennis, P. A., Rizvi, N. A., Paz-Ares Rodriguez, L., ... Investigators, ATLANTIC. (2018). Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. The Lancet Oncology, 19(4), 521-536. https://doi.org/10.1016/S1470-2045(18)30144-X

Garassino, MC, Cho, B-C, Kim, J-H, Mazières, J, Vansteenkiste, J, Lena, H, Corral Jaime, J, Gray, JE, Powderly, J, Chouaid, C, Bidoli, P, Wheatley-Price, P, Park, K, Soo, RA, Huang, Y, Wadsworth, C, Dennis, PA, Rizvi, NA, Paz-Ares Rodriguez, L, Novello, S, Hiret, S, Schmid, P, Laack, E, Califano, R, Maemondo, M, Kim, S-W, Chaft, J, Vicente Baz, D, Berghmans, T, Kim, D-W, Surmont, V, Reck, M, Han, J-Y, Holgado Martin, E, Belda Iniesta, C, Oe, Y, Chella, A, Chopra, A, Robinet, G, Soto Parra, H, Thomas, M, Cheema, P, Katakami, N, Su, W-C, Kim, Y-C, Wolf, J, Lee, J-S, Saka, H, Milella, M, Ramos Garcia, I, Sibille, A, Yokoi, T, Kang, EJ, Atagi, S, Spaeth-Schwalbe, E, Nishio, M, Imamura, F, Gabrail, N, Veillon, R, Derijcke, S, Maeda, T, Zylla, D, Kubiak, K, Santoro, A, Uy, MN, Lucien Geater, S, Italiano, A, Kowalski, D, Barlesi, F, Chen, Y-M, Spigel, D, Chewaskulyong, B, Garcia Gomez, R, Alvarez Alvarez, R, Yang, C-H, Hsia, T-C, Denis, F, Sakai, H, Vincent, M, Goto, K, Bosch-Barrera, J, Weiss, G, Canon, J-L, Scholz, C, Aglietta, M, Kemmotsu, H, Azuma, K, Bradbury, P, Feld, R, Chachoua, A, Jassem, J, Juergens, R, Palmero Sanchez, R, Malcolm, A, Vrindavanam, N, Kubota, K, Waller, C, Waterhouse, D, Coudert, B, Mark, Z, Satouchi, M, Chang, G-C, Herzmann, C, Chaudhry, A, Giridharan, S, Hesketh, P, Ikeda, N, Boccia, R, Iannotti, N, Haigentz, M, Reynolds, J, Querol, J, Nakagawa, K, Sugawara, S, Tan, EH, Hirashima, T, Gettinger, S, Kato, T, Takeda, K, Juan Vidal, O, Mohn-Staudner, A, Panwalkar, A, Daniel, D, Kobayashi, K, Ladrera, GEI, Schulte, C, Sebastian, M, Cernovska, M, Coupkova, H, Havel, L, Pauk, N, Singh, J, Murakami, S, Csoszi, T, Losonczy, G, Price, A, Anderson, I, Iqbal, M, Torri, V, Juhasz, E, Khanani, S, Koubkova, L, Levy, B, Page, R, Bocskei, C, Crinò, L, Einspahr, D, Hagenstad, C, Juat, N, Overton, L, Garrison, M, Szalai, Z & Investigators, ATLANTIC 2018, 'Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study', The Lancet Oncology, vol. 19, no. 4, pp. 521-536. https://doi.org/10.1016/S1470-2045(18)30144-X

@article{aff5453431e340d0a5c2a032175b3fcc,

title = "Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study",

author = "M.C. Garassino and B.-C. Cho and J.-H. Kim and J. Mazi{\`e}res and J. Vansteenkiste and H. Lena and {Corral Jaime}, J. and J.E. Gray and J. Powderly and C. Chouaid and P. Bidoli and P. Wheatley-Price and K. Park and R.A. Soo and Y. Huang and C. Wadsworth and P.A. Dennis and N.A. Rizvi and {Paz-Ares Rodriguez}, L. and S. Novello and S. Hiret and P. Schmid and E. Laack and R. Califano and M. Maemondo and S.-W. Kim and J. Chaft and {Vicente Baz}, D. and T. Berghmans and D.-W. Kim and V. Surmont and M. Reck and J.-Y. Han and {Holgado Martin}, E. and {Belda Iniesta}, C. and Y. Oe and A. Chella and A. Chopra and G. Robinet and {Soto Parra}, H. and M. Thomas and P. Cheema and N. Katakami and W.-C. Su and Y.-C. Kim and J. Wolf and J.-S. Lee and H. Saka and M. Milella and {Ramos Garcia}, I. and A. Sibille and T. Yokoi and E.J. Kang and S. Atagi and E. Spaeth-Schwalbe and M. Nishio and F. Imamura and N. Gabrail and R. Veillon and S. Derijcke and T. Maeda and D. Zylla and K. Kubiak and A. Santoro and M.N. Uy and {Lucien Geater}, S. and A. Italiano and D. Kowalski and F. Barlesi and Y.-M. Chen and D. Spigel and B. Chewaskulyong and {Garcia Gomez}, R. and {Alvarez Alvarez}, R. and C.-H. Yang and T.-C. Hsia and F. Denis and H. Sakai and M. Vincent and K. Goto and J. Bosch-Barrera and G. Weiss and J.-L. Canon and C. Scholz and M. Aglietta and H. Kemmotsu and K. Azuma and P. Bradbury and R. Feld and A. Chachoua and J. Jassem and R. Juergens and {Palmero Sanchez}, R. and A. Malcolm and N. Vrindavanam and K. Kubota and C. Waller and D. Waterhouse and B. Coudert and Z. Mark and M. Satouchi and G.-C. Chang and C. Herzmann and A. Chaudhry and S. Giridharan and P. Hesketh and N. Ikeda and R. Boccia and N. Iannotti and M. Haigentz and J. Reynolds and J. Querol and K. Nakagawa and S. Sugawara and E.H. Tan and T. Hirashima and S. Gettinger and T. Kato and K. Takeda and {Juan Vidal}, O. and A. Mohn-Staudner and A. Panwalkar and D. Daniel and K. Kobayashi and G.E.I. Ladrera and C. Schulte and M. Sebastian and M. Cernovska and H. Coupkova and L. Havel and N. Pauk and J. Singh and S. Murakami and T. Csoszi and G. Losonczy and A. Price and I. Anderson and M. Iqbal and V. Torri and E. Juhasz and S. Khanani and L. Koubkova and B. Levy and R. Page and C. Bocskei and L. Crin{\`o} and D. Einspahr and C. Hagenstad and N. Juat and L. Overton and M. Garrison and Z. Szalai and ATLANTIC Investigators",

note = "cited By 36",

year = "2018",

doi = "10.1016/S1470-2045(18)30144-X",

language = "Non definita",

volume = "19",

pages = "521--536",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "4",

}

TY - JOUR

T1 - Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

AU - Garassino, M.C.

AU - Cho, B.-C.

AU - Kim, J.-H.

AU - Mazières, J.

AU - Vansteenkiste, J.

AU - Lena, H.

AU - Corral Jaime, J.

AU - Gray, J.E.

AU - Powderly, J.

AU - Chouaid, C.

AU - Bidoli, P.

AU - Wheatley-Price, P.

AU - Park, K.

AU - Soo, R.A.

AU - Huang, Y.

AU - Wadsworth, C.

AU - Dennis, P.A.

AU - Rizvi, N.A.

AU - Paz-Ares Rodriguez, L.

AU - Novello, S.

AU - Hiret, S.

AU - Schmid, P.

AU - Laack, E.

AU - Califano, R.

AU - Maemondo, M.

AU - Kim, S.-W.

AU - Chaft, J.

AU - Vicente Baz, D.

AU - Berghmans, T.

AU - Kim, D.-W.

AU - Surmont, V.

AU - Reck, M.

AU - Han, J.-Y.

AU - Holgado Martin, E.

AU - Belda Iniesta, C.

AU - Oe, Y.

AU - Chella, A.

AU - Chopra, A.

AU - Robinet, G.

AU - Soto Parra, H.

AU - Thomas, M.

AU - Cheema, P.

AU - Katakami, N.

AU - Su, W.-C.

AU - Kim, Y.-C.

AU - Wolf, J.

AU - Lee, J.-S.

AU - Saka, H.

AU - Milella, M.

AU - Ramos Garcia, I.

AU - Sibille, A.

AU - Yokoi, T.

AU - Kang, E.J.

AU - Atagi, S.

AU - Spaeth-Schwalbe, E.

AU - Nishio, M.

AU - Imamura, F.

AU - Gabrail, N.

AU - Veillon, R.

AU - Derijcke, S.

AU - Maeda, T.

AU - Zylla, D.

AU - Kubiak, K.

AU - Santoro, A.

AU - Uy, M.N.

AU - Lucien Geater, S.

AU - Italiano, A.

AU - Kowalski, D.

AU - Barlesi, F.

AU - Chen, Y.-M.

AU - Spigel, D.

AU - Chewaskulyong, B.

AU - Garcia Gomez, R.

AU - Alvarez Alvarez, R.

AU - Yang, C.-H.

AU - Hsia, T.-C.

AU - Denis, F.

AU - Sakai, H.

AU - Vincent, M.

AU - Goto, K.

AU - Bosch-Barrera, J.

AU - Weiss, G.

AU - Canon, J.-L.

AU - Scholz, C.

AU - Aglietta, M.

AU - Kemmotsu, H.

AU - Azuma, K.

AU - Bradbury, P.

AU - Feld, R.

AU - Chachoua, A.

AU - Jassem, J.

AU - Juergens, R.

AU - Palmero Sanchez, R.

AU - Malcolm, A.

AU - Vrindavanam, N.

AU - Kubota, K.

AU - Waller, C.

AU - Waterhouse, D.

AU - Coudert, B.

AU - Mark, Z.

AU - Satouchi, M.

AU - Chang, G.-C.

AU - Herzmann, C.

AU - Chaudhry, A.

AU - Giridharan, S.

AU - Hesketh, P.

AU - Ikeda, N.

AU - Boccia, R.

AU - Iannotti, N.

AU - Haigentz, M.

AU - Reynolds, J.

AU - Querol, J.

AU - Nakagawa, K.

AU - Sugawara, S.

AU - Tan, E.H.

AU - Hirashima, T.

AU - Gettinger, S.

AU - Kato, T.

AU - Takeda, K.

AU - Juan Vidal, O.

AU - Mohn-Staudner, A.

AU - Panwalkar, A.

AU - Daniel, D.

AU - Kobayashi, K.

AU - Ladrera, G.E.I.

AU - Schulte, C.

AU - Sebastian, M.

AU - Cernovska, M.

AU - Coupkova, H.

AU - Havel, L.

AU - Pauk, N.

AU - Singh, J.

AU - Murakami, S.

AU - Csoszi, T.

AU - Losonczy, G.

AU - Price, A.

AU - Anderson, I.

AU - Iqbal, M.

AU - Torri, V.

AU - Juhasz, E.

AU - Khanani, S.

AU - Koubkova, L.

AU - Levy, B.

AU - Page, R.

AU - Bocskei, C.

AU - Crinò, L.

AU - Einspahr, D.

AU - Hagenstad, C.

AU - Juat, N.

AU - Overton, L.

AU - Garrison, M.

AU - Szalai, Z.

AU - Investigators, ATLANTIC

N1 - cited By 36

PY - 2018

Y1 - 2018

U2 - 10.1016/S1470-2045(18)30144-X

DO - 10.1016/S1470-2045(18)30144-X

M3 - Articolo

SN - 1470-2045

VL - 19

SP - 521

EP - 536

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 4

ER -